|
molecular tumour board |
10 |
|
next-generation sequencing |
10 |
|
precision oncology |
10 |
|
sequence-directed therapy |
10 |
|
brca1 |
6 |
|
brca1 protein - genetics |
6 |
|
brca2 |
6 |
|
brca2 protein - genetics |
6 |
|
breast cancer susceptibility gene |
6 |
|
breast neoplasms - genetics - pathology |
6 |
|
drug resistance |
6 |
|
gene mutation |
6 |
|
genetic predisposition to disease - genetics |
6 |
|
nasopharyngeal carcinoma |
6 |
|
open reading frames - genetics |
6 |
|
palbociclib |
6 |
|
patient-derived xenografts |
6 |
|
saha |
6 |
|
igf-1r |
5 |
|
ovarian cancer |
5 |
|
pi3k |
5 |
|
targeted therapy |
5 |
|
antibodies - pharmacology |
4 |
|
breast cancer |
4 |
|
cadherins - antagonists and inhibitors - genetics - physiology |
4 |
|
carcinoma - genetics - pathology |
4 |
|
catenins - genetics - metabolism - physiology |
4 |
|
cell division - drug effects |
4 |
|
cell line, transformed |
4 |
|
cell line, tumor |
4 |
|
combination therapy |
4 |
|
epithelial cells - pathology |
4 |
|
estradiol - pharmacology |
4 |
|
eye proteins - antagonists & inhibitors - genetics - pharmacology |
4 |
|
female |
4 |
|
gene expression - drug effects |
4 |
|
gnrh |
4 |
|
humans |
4 |
|
immunohistochemistry |
4 |
|
in situ nick-end labeling |
4 |
|
light at night |
4 |
|
light pollution |
4 |
|
mapk |
4 |
|
melatonin |
4 |
|
meta-analysis |
4 |
|
motility |
4 |
|
nerve growth factors - antagonists & inhibitors - genetics - pharmacology |
4 |
|
ovarian neoplasms - genetics - pathology |
4 |
|
ovarian neoplasms - pathology |
4 |
|
ovary - pathology |
4 |
|
p-cadherin |
4 |
|
p120ctn |
4 |
|
polymerase chain reaction |
4 |
|
receptor, igf type 1 - antagonists and inhibitors - genetics - physiology |
4 |
|
reverse transcriptase polymerase chain reaction |
4 |
|
rna, messenger - analysis |
4 |
|
rna, small interfering - pharmacology |
4 |
|
serpins - genetics - pharmacology |
4 |
|
3d spheroid based drug sensitivity assay |
3 |
|
angiogenesis |
3 |
|
angiogenesis inducing agents - pharmacology |
3 |
|
animal cell |
3 |
|
autophagy (cellular) |
3 |
|
bioassay |
3 |
|
cancer mutations |
3 |
|
carcinogenesis |
3 |
|
chemotherapy |
3 |
|
combigem |
3 |
|
combination treatment |
3 |
|
combinatorial genetics |
3 |
|
crispr |
3 |
|
endothelial cells |
3 |
|
endothelial cells - drug effects - metabolism |
3 |
|
enos |
3 |
|
gain‐of‐function mutations |
3 |
|
ginseng |
3 |
|
ginsenosides - pharmacology |
3 |
|
high-throughput screening |
3 |
|
huvec |
3 |
|
immunotherapy |
3 |
|
induced pluripotency |
3 |
|
metastasis |
3 |
|
mutation |
3 |
|
neovascularization, physiologic - drug effects |
3 |
|
oestrogen receptor |
3 |
|
pedf |
3 |
|
pi3k/akt |
3 |
|
protein degradation |
3 |
|
receptor cross-talk - drug effects |
3 |
|
signalling |
3 |
|
sox17 |
3 |
|
variants of uncertain significance |
3 |
|
akt signaling |
2 |
|
animal experiment |
2 |
|
animal model |
2 |
|
animal tissue |
2 |
|
antineoplastic activity |
2 |
|
base sequence |
2 |
|
cadherin |
2 |
|
cadherins - genetics - metabolism |
2 |
|
cadherins - physiology |
2 |
|
catenins - physiology |
2 |
|
cell movement - drug effects |
2 |
|
cell movement - drug effects - physiology |
2 |
|
cp: cancer |
2 |
|
cross-talk |
2 |
|
dna repair |
2 |
|
down-regulation - drug effects |
2 |
|
endocrine resistance |
2 |
|
enzyme activation - drug effects |
2 |
|
enzyme induction - drug effects |
2 |
|
epidermal growth factor receptor |
2 |
|
erlotinib |
2 |
|
estrogen receptor |
2 |
|
estrogen receptor alpha - metabolism |
2 |
|
estrogen receptor beta - metabolism |
2 |
|
extrapituitary |
2 |
|
gnrh receptor |
2 |
|
gonadotropin-releasing hormone - pharmacology |
2 |
|
gonadotropin-releasing hormone - physiology |
2 |
|
invasion |
2 |
|
jnk mitogen-activated protein kinases - metabolism |
2 |
|
luminal breast cancer |
2 |
|
luteinizing hormone releasing hormone - receptors. |
2 |
|
matrix metalloproteinase 2 - antagonists & inhibitors - biosynthesis - genetics - metabolism |
2 |
|
matrix metalloproteinase 9 - antagonists & inhibitors - biosynthesis - genetics - metabolism |
2 |
|
matrix metalloproteinases |
2 |
|
metastasis. |
2 |
|
neoplasm invasiveness |
2 |
|
ovarian neoplasms - enzymology - genetics - pathology |
2 |
|
ovarian neoplasms - genetics - metabolism - physiopathology - secondary |
2 |
|
ovaries - cancer. |
2 |
|
ovaries -- cancer. |
2 |
|
p38 mapk |
2 |
|
p85 |
2 |
|
p85 regulatory subunit |
2 |
|
pik3r1 |
2 |
|
pituitary |
2 |
|
promoter regions, genetic - drug effects |
2 |
|
receptor tyrosine kinase |
2 |
|
receptors, lhrh - biosynthesis - genetics |
2 |
|
rna, messenger - biosynthesis - genetics |
2 |
|
rna, small interfering - genetics |
2 |
|
signal transduction - drug effects |
2 |
|
signal transduction - physiology |
2 |
|
signaling |
2 |
|
transcription factors - antagonists & inhibitors - genetics - metabolism |
2 |
|
transfection |
2 |
|
tumor |
2 |
|
up-regulation - drug effects |
2 |
|
autophagy |
1 |
|
axl |
1 |
|
axl receptor tyrosine kinase |
1 |
|
biomarkers |
1 |
|
cancer |
1 |
|
cellular assay |
1 |
|
clinical marker |
1 |
|
driver mutation |
1 |
|
drug sensitivity |
1 |
|
endometrial cancer |
1 |
|
functional genomics |
1 |
|
functional proteomics |
1 |
|
growth arrest-specific protein 6 |
1 |
|
kras |
1 |
|
mek inhibitor |
1 |
|
neomorph |
1 |
|
p85a |
1 |
|
p85α |
1 |
|
pi3k inhibitor |
1 |
|
pik3ca |
1 |
|
protein signalling |
1 |
|
pten loss |
1 |
|
receptor tyrosine kinases |
1 |
|
tcga |
1 |
|
therapeutic target |
1 |
|
tp-0903 |
1 |
